posted on 2017-11-09, 14:41authored byAmina Jindani
The INTERTB Annual Symposium takes place at St. George’s, University of
London to discuss the latest developments in tuberculosis. Speakers and
participants from many countries meet to discuss the most recent
findings, both preclinical and clinical, that could lead to the eventual
elimination of tuberculosis.
The International Consortium for Trials of Chemotherapeutic Agents in
Tuberculosis (INTERTB) is a not-for-profit charitable organisation
responsible for designing, conducting and analysing randomised
controlled clinical trials to be carried out in countries with a high
burden of tuberculosis. The primary objective of these trials are to
define regimens of treatment which will have high cure rates and will be
simple to administer by the National Tuberculosis Programmes of these
countries.
Because of their importance in assessing the activity
of new antituberculosis drugs, basic studies of factors affecting
response to chemotherapy and the study of surrogate markers of relapse
forms a major part of the work of the consortium.
In addition,
capacity strengthening to increase the ability of centres to participate
in trials is an integral part of the consortium’s functions. Expertise
is available in trial design and analysis and in laboratory techniques.
The
INTERTB Coordinating Centre is based at St. George’s, University of London in
the United Kingdom.